Catuai Rojo Coffee (Coffea arabica)
Catuai Rojo is an Arabica coffee cultivar containing approximately 1.41–1.42% caffeine and notable concentrations of chlorogenic acids, which inhibit adenosine receptors and modulate glucose metabolism via glucose-6-phosphatase inhibition. These bioactive compounds contribute to its potential stimulant and antioxidant properties, though no clinical trials have been conducted specifically on this cultivar.

Origin & History
Catuai Rojo is a cultivar of Coffea arabica that originated from a cross between Mundo Novo and Caturra varieties, released commercially in 1983 after selection by IHCAFÉ (the Honduran Coffee Institute). The beans are sourced from the fruit (cherry) of the coffee plant and processed through standard post-harvest methods including wet process, natural process, pulped natural process, or mechanical demucilaging.
Historical & Cultural Context
No information about traditional medicine use of Catuai Rojo specifically, or its historical context in traditional medicine systems, is provided in the available research. The cultivar was developed relatively recently in 1983 as a commercial coffee variety.
Health Benefits
• Contains 1.41-1.42% caffeine content which may support alertness and cognitive function (evidence quality: not clinically studied in this cultivar) • Rich in chlorogenic acids and phenolic compounds that may provide antioxidant activity (evidence quality: chemical composition data only) • Contains 13.11-13.26% protein content which contributes to nutritional value (evidence quality: compositional analysis only) • Lipid content of 5.98-7.67% including linoleic acid (40-45%) may support metabolic health (evidence quality: no clinical trials available) • Higher altitude cultivation produces beans with increased protein, caffeine, and lipid content (evidence quality: agricultural research only)
How It Works
Caffeine in Catuai Rojo acts primarily as a competitive antagonist at adenosine A1 and A2A receptors in the central nervous system, blocking adenosine-mediated inhibitory signaling to promote wakefulness and cognitive arousal. Chlorogenic acids, particularly 5-caffeoylquinic acid, inhibit hepatic glucose-6-phosphatase, potentially slowing postprandial glucose absorption and modulating insulin sensitivity. These phenolic compounds also scavenge reactive oxygen species and chelate pro-oxidant metal ions, contributing to measurable antioxidant capacity as assessed by DPPH and FRAP assays.
Scientific Research
No human clinical trials, randomized controlled trials, or meta-analyses specific to Catuai Rojo coffee or its health effects were found in the provided research. The available studies focus exclusively on chemical composition and sensory characteristics rather than clinical outcomes.
Clinical Summary
No clinical trials have been conducted specifically on Catuai Rojo Coffee as a distinct cultivar; available evidence is limited to chemical composition analyses and agricultural studies. General Coffea arabica research supports caffeine's cognitive and alertness benefits at doses of 75–200 mg, with randomized controlled trials in healthy adults showing improved reaction time and sustained attention. Chlorogenic acid research in broader coffee populations suggests modest reductions in fasting blood glucose and blood pressure, though effect sizes are small and cultivar-specific contributions remain unconfirmed. Catuai Rojo's caffeine content of 1.41–1.42% falls within the typical Arabica range, making general caffeine pharmacology cautiously applicable, but cultivar-specific clinical claims are not currently supported.
Nutritional Profile
Catuai Rojo Coffee (Coffea arabica) green bean compositional data: Protein: 13.11-13.26% dry weight basis (comprising all essential amino acids; bioavailability significantly altered by roasting via Maillard reactions). Total lipids: approximately 12-16% dry weight (typical Arabica range; primarily triacylglycerols and diterpenes cafestol and kahweol at ~0.2-0.4% — bioavailability dependent on brewing method, with filtered coffee removing most diterpenes). Carbohydrates: approximately 60% dry weight (sucrose ~6-9% in green beans, largely degraded during roasting; polysaccharides including galactomannans and arabinogalactans constitute majority). Caffeine: 1.41-1.42% dry weight (well-absorbed alkaloid, ~99% bioavailability upon oral ingestion). Chlorogenic acids (CGA): estimated 6-10% dry weight in green beans (primarily 5-caffeoylquinic acid); reduced 50-80% during roasting; bioavailability of remaining CGAs is moderate (~30% absorbed in small intestine, remainder metabolized by colonic microbiota). Trigonelline: approximately 0.5-1.0% dry weight (precursor to niacin/vitamin B3 upon roasting, contributing meaningful B3 content to brewed coffee). Minerals per 100g brewed coffee (approximate): potassium 49-116mg, magnesium 7-24mg, manganese 0.05-0.1mg, phosphorus 3-7mg. Niacin equivalents from trigonelline degradation: ~0.5-1.0mg per 200ml serving. Dietary fiber (as brewed beverage): negligible; unfiltered preparations may contain trace soluble fiber from polysaccharides. Bioactive diterpenes cafestol and kahweol: present in unfiltered brewing methods at physiologically relevant concentrations; absent in paper-filtered coffee. Note: all roasted/brewed values are estimates derived from general Arabica data; cultivar-specific post-roast nutritional analysis for Catuai Rojo is not formally published.
Preparation & Dosage
No clinically studied dosage ranges specific to Catuai Rojo coffee are documented in the available research. The studies address chemical composition rather than therapeutic dosing protocols. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Other coffee cultivars, L-theanine, green tea extract, rhodiola, B-complex vitamins
Safety & Interactions
Catuai Rojo Coffee shares the safety profile of Coffea arabica, with caffeine intake above 400 mg/day in healthy adults associated with anxiety, insomnia, tachycardia, and gastrointestinal irritation. Caffeine is a substrate and inhibitor of CYP1A2 and may potentiate the effects of stimulant medications, increase lithium excretion, and reduce the efficacy of adenosine-based cardiac drugs. Chlorogenic acids may mildly enhance the hypoglycemic effect of antidiabetic medications, warranting monitoring in diabetic patients. Pregnant individuals should limit caffeine intake to under 200 mg/day per major health guidelines, and individuals with anxiety disorders, arrhythmias, or GERD should use caffeine-containing products cautiously.